# Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a company headquartered in Waltham, MA, United States.

## Company overview

- **Legal name:** Deciphera Pharmaceuticals, Inc.
- **Former names in filing history:** Deciphera Pharmaceuticals, LLC (2015-09-29 to 2017-08-15)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Waltham, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001654151

## About

Deciphera Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001654151, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-02-07, it reported annual revenue of USD 163,356,000; net income of USD -194,942,000; total assets of USD 473,566,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $163.4M (USD 163,356,000)
- **Net income:** -$194.9M (USD -194,942,000)
- **Total assets:** $473.6M (USD 473,566,000)
- **Cash and equivalents:** $83.5M (USD 83,507,000)
- **Operating cash flow:** -$146.7M (USD -146,697,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $134.0M (USD 134,036,000)
- **Net income:** -$178.9M (USD -178,931,000)
- **Total assets:** $454.0M (USD 454,039,000)
- **Cash and equivalents:** $64.7M (USD 64,741,000)
- **Operating cash flow:** -$152.9M (USD -152,862,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $96.1M (USD 96,148,000)
- **Net income:** -$300.0M (USD -299,964,000)
- **Total assets:** $429.5M (USD 429,484,000)
- **Cash and equivalents:** $87.1M (USD 87,063,000)
- **Operating cash flow:** -$240.8M (USD -240,824,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $42.1M (USD 42,087,000)
- **Net income:** -$266.5M (USD -266,489,000)
- **Total assets:** $642.4M (USD 642,432,000)
- **Cash and equivalents:** $135.9M (USD 135,897,000)
- **Operating cash flow:** -$239.7M (USD -239,683,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2024-06-11 — period 2024-06-11 — 8-K
- Form 10-Q — filed 2024-05-10 — period 2024-03-31 — 10-Q
- Form 8-K — filed 2024-04-29 — period 2024-04-29 — 8-K
- Form DEF 14A — filed 2024-04-25 — period 2024-06-20 — DEF 14A
- Form 10-K — filed 2024-02-07 — period 2023-12-31 — 10-K
- Form 8-K — filed 2024-02-06 — period 2024-02-06 — 8-K
- Form 8-K — filed 2024-01-08 — period 2024-01-08 — FORM 8-K
- Form 10-Q — filed 2023-10-30 — period 2023-09-30 — 10-Q
- Form 8-K — filed 2023-10-30 — period 2023-10-30 — 8-K
- Form 10-Q — filed 2023-08-09 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-08-09 — period 2023-08-09 — 8-K
- Form 8-K — filed 2023-08-03 — period 2023-08-01 — 8-K

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/deciphera-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology